BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 22791287)

  • 1. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency.
    Hassan A; Booth C; Brightwell A; Allwood Z; Veys P; Rao K; Hönig M; Friedrich W; Gennery A; Slatter M; Bredius R; Finocchi A; Cancrini C; Aiuti A; Porta F; Lanfranchi A; Ridella M; Steward C; Filipovich A; Marsh R; Bordon V; Al-Muhsen S; Al-Mousa H; Alsum Z; Al-Dhekri H; Al Ghonaium A; Speckmann C; Fischer A; Mahlaoui N; Nichols KE; Grunebaum E; Al Zahrani D; Roifman CM; Boelens J; Davies EG; Cavazzana-Calvo M; Notarangelo L; Gaspar HB;
    Blood; 2012 Oct; 120(17):3615-24; quiz 3626. PubMed ID: 22791287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency.
    Dvorak CC; Hassan A; Slatter MA; Hönig M; Lankester AC; Buckley RH; Pulsipher MA; Davis JH; Güngör T; Gabriel M; Bleesing JH; Bunin N; Sedlacek P; Connelly JA; Crawford DF; Notarangelo LD; Pai SY; Hassid J; Veys P; Gennery AR; Cowan MJ
    J Allergy Clin Immunol; 2014 Oct; 134(4):935-943.e15. PubMed ID: 25109802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
    Hashem H; Bucciol G; Ozen S; Unal S; Bozkaya IO; Akarsu N; Taskinen M; Koskenvuo M; Saarela J; Dimitrova D; Hickstein DD; Hsu AP; Holland SM; Krance R; Sasa G; Kumar AR; Müller I; de Sousa MA; Delafontaine S; Moens L; Babor F; Barzaghi F; Cicalese MP; Bredius R; van Montfrans J; Baretta V; Cesaro S; Stepensky P; Benedicte N; Moshous D; Le Guenno G; Boutboul D; Dalal J; Brooks JP; Dokmeci E; Dara J; Lucas CL; Hambleton S; Wilson K; Jolles S; Koc Y; Güngör T; Schnider C; Candotti F; Steinmann S; Schulz A; Chambers C; Hershfield M; Ombrello A; Kanakry JA; Meyts I
    J Clin Immunol; 2021 Oct; 41(7):1633-1647. PubMed ID: 34324127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Immune Recovery After Hematopoietic Stem Cell Transplantation for ADA Deficiency: a Single-Center Experience.
    Kreins AY; Velasco HF; Cheong KN; Rao K; Veys P; Worth A; Gaspar HB; Booth C
    J Clin Immunol; 2022 Jan; 42(1):94-107. PubMed ID: 34654999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCT survival in ADA-SCID: what's the buzz?
    Chan SK; Shearer WT
    Blood; 2012 Oct; 120(17):3392-3. PubMed ID: 23100302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
    Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
    Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006).
    Booth C; Hershfield M; Notarangelo L; Buckley R; Hoenig M; Mahlaoui N; Cavazzana-Calvo M; Aiuti A; Gaspar HB
    Clin Immunol; 2007 May; 123(2):139-47. PubMed ID: 17300989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC.
    Cuvelier GDE; Logan BR; Prockop SE; Buckley RH; Kuo CY; Griffith LM; Liu X; Yip A; Hershfield MS; Ayoub PG; Moore TB; Dorsey MJ; O'Reilly RJ; Kapoor N; Pai SY; Kapadia M; Ebens CL; Forbes Satter LR; Burroughs LM; Petrovic A; Chellapandian D; Heimall J; Shyr DC; Rayes A; Bednarski JJ; Chandra S; Chandrakasan S; Gillio AP; Madden L; Quigg TC; Caywood EH; Dávila Saldaña BJ; DeSantes K; Eissa H; Goldman FD; Rozmus J; Shah AJ; Vander Lugt MT; Thakar MS; Parrott RE; Martinez C; Leiding JW; Torgerson TR; Pulsipher MA; Notarangelo LD; Cowan MJ; Dvorak CC; Haddad E; Puck JM; Kohn DB
    Blood; 2022 Aug; 140(7):685-705. PubMed ID: 35671392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency.
    Hassan A; Lee P; Maggina P; Xu JH; Moreira D; Slatter M; Nademi Z; Worth A; Adams S; Jones A; Cale C; Allwood Z; Rao K; Chiesa R; Amrolia P; Gaspar H; Davies EG; Veys P; Gennery A; Qasim W
    J Allergy Clin Immunol; 2014 Jun; 133(6):1660-6. PubMed ID: 24794685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications.
    Hönig M; Albert MH; Schulz A; Sparber-Sauer M; Schütz C; Belohradsky B; Güngör T; Rojewski MT; Bode H; Pannicke U; Lippold D; Schwarz K; Debatin KM; Hershfield MS; Friedrich W
    Blood; 2007 Apr; 109(8):3595-602. PubMed ID: 17185467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic Cell Transplantation for Adenosine Deaminase Severe Combined Immunodeficiency-Improved Outcomes in the Modern Era.
    Ghimenton E; Flinn A; Lum SH; Leahy TR; Nademi Z; Owens S; Williams E; Flood T; Hambleton S; Slatter M; Gennery AR
    J Clin Immunol; 2022 May; 42(4):819-826. PubMed ID: 35288820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Cicalese MP; Ferrua F; Castagnaro L; Pajno R; Barzaghi F; Giannelli S; Dionisio F; Brigida I; Bonopane M; Casiraghi M; Tabucchi A; Carlucci F; Grunebaum E; Adeli M; Bredius RG; Puck JM; Stepensky P; Tezcan I; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Ciceri F; Roncarolo MG; Aiuti A
    Blood; 2016 Jul; 128(1):45-54. PubMed ID: 27129325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.
    Ferrua F; Brigida I; Aiuti A
    Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):551-6. PubMed ID: 20966749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplantation outcomes for severe combined immunodeficiency, 2000-2009.
    Pai SY; Logan BR; Griffith LM; Buckley RH; Parrott RE; Dvorak CC; Kapoor N; Hanson IC; Filipovich AH; Jyonouchi S; Sullivan KE; Small TN; Burroughs L; Skoda-Smith S; Haight AE; Grizzle A; Pulsipher MA; Chan KW; Fuleihan RL; Haddad E; Loechelt B; Aquino VM; Gillio A; Davis J; Knutsen A; Smith AR; Moore TB; Schroeder ML; Goldman FD; Connelly JA; Porteus MH; Xiang Q; Shearer WT; Fleisher TA; Kohn DB; Puck JM; Notarangelo LD; Cowan MJ; O'Reilly RJ
    N Engl J Med; 2014 Jul; 371(5):434-46. PubMed ID: 25075835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of efficacy and prognosis of allogeneic hematopoietic stem cell transplantation for the treatment of combined immunodeficiency].
    Wang P; Qian XW; Jiang WJ; Wang HS; Hou J; Sun JQ; Wang XC; Zhai XW
    Zhonghua Er Ke Za Zhi; 2024 May; 62(5):444-450. PubMed ID: 38623012
    [No Abstract]   [Full Text] [Related]  

  • 17. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
    Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
    J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of enzyme replacement therapy on immune function in ADA deficiency patient.
    Nakazawa Y; Kawai T; Uchiyama T; Goto F; Watanabe N; Maekawa T; Ishiguro A; Okuyama T; Otsu M; Yamada M; Hershfield MS; Ariga T; Onodera M
    Clin Immunol; 2015 Dec; 161(2):391-3. PubMed ID: 26122173
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.